newsfilter
← Latest News
Business Wire·

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced it will regain global commercialization rights to FAMPYRA® (fampridine) following a decision by Biogen to terminate the license and collaboration agreement